Programmed Cell Death Ligand 1 Expression in Cytological and Surgical Non–Small Cell Lung Cancer Specimens in Association with EGFR Mutation and Overall Survival: A Single-Institution Experience
| dc.contributor.author | Gökal, Elif Sayman | |
| dc.contributor.author | Aker, Fügen | |
| dc.contributor.author | Sılav, Zuhal Kus | |
| dc.contributor.author | Öven, Bala Başak | |
| dc.date.accessioned | 2024-08-04T19:54:41Z | |
| dc.date.available | 2024-08-04T19:54:41Z | |
| dc.date.issued | 2022 | |
| dc.department | İnönü Üniversitesi | en_US |
| dc.description.abstract | Objective: The aim of this study was to evaluate programmed cell death ligand-1 (PD-L1) expression and the relationship between driver mutations and survival analysis in advanced-stage non-small cell lung carcinoma (NSCLC). Material and Method: A total of 122 advanced-stage NSCLC patients were included in this retrospective study. The patients were diagnosed based on cytological examination and histopathological analysis of biopsy or resection material that had undergone at least 1 molecular analysis. The expression of PD-L1 in tumors and tumor-infiltrating lymphocytes (TIL) was scored and compared with age, sex, organ, biopsy method, tumor subtype, driver mutation status, and overall survival data. Results: There was no statistically significant difference between PD-L1-positivity and age, gender, location, pattern, or pathological diagnosis of the type of sample. When the threshold value for PD-L1 IHC evaluation was accepted as ?1% and ?50%, the rate of positivity was 19.7% and 7.4%, respectively. Conclusion: Since there is a wide range of positivity rates reported in the literature, we could not reach a conclusion as to whether the PD-L1-positivity rate we observed was high or low. There is a need for comparative studies where the technique, clones, threshold values, and phases are homogenized. There is an inverse correlation between the EGFR-mutant population and PD-L1 positivity. In terms of overall survival, no relationship was found between PD-L1 positivity, the presence of TIL, and EGFR mutation status. | en_US |
| dc.identifier.endpage | 274 | en_US |
| dc.identifier.issn | 1018-5615 | |
| dc.identifier.issn | 1309-5730 | |
| dc.identifier.issue | 3 | en_US |
| dc.identifier.startpage | 261 | en_US |
| dc.identifier.trdizinid | 1129974 | en_US |
| dc.identifier.uri | https://search.trdizin.gov.tr/yayin/detay/1129974 | |
| dc.identifier.uri | https://hdl.handle.net/11616/90058 | |
| dc.identifier.volume | 38 | en_US |
| dc.indekslendigikaynak | TR-Dizin | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Türk Patoloji Dergisi | en_US |
| dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Programmed Cell Death Ligand 1 Expression in Cytological and Surgical Non–Small Cell Lung Cancer Specimens in Association with EGFR Mutation and Overall Survival: A Single-Institution Experience | en_US |
| dc.type | Article | en_US |
